Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion and 3.5-4 hours thereafter, thus making darat...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Francesca Bonello, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Roberto Mina
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-03-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	multiple myeloma daratumumab rapid infusion real life infusion-related reactions
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2022.851864/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!